Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 310,274,432
  • Shares Outstanding, K 1,767,140
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • EBIT $ 13,822 M
  • EBITDA $ 22,520 M
  • 60-Month Beta 0.58
  • Price/Sales 5.71
  • Price/Cash Flow 11.10
  • Price/Book 51.11

Options Overview Details

View History
  • Implied Volatility 23.08% ( +0.40%)
  • Historical Volatility 44.10%
  • IV Percentile 73%
  • IV Rank 49.80%
  • IV High 30.36% on 10/29/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 7,393
  • Volume Avg (30-Day) 22,173
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 391,839
  • Open Int (30-Day) 437,089

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.99
  • Number of Estimates 10
  • High Estimate 3.10
  • Low Estimate 2.96
  • Prior Year 2.79
  • Growth Rate Est. (year over year) +7.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
170.21 +2.94%
on 12/17/24
184.24 -4.90%
on 11/27/24
-1.74 (-0.98%)
since 11/22/24
3-Month
163.81 +6.96%
on 11/19/24
207.32 -15.49%
on 10/31/24
-18.62 (-9.61%)
since 09/23/24
52-Week
153.58 +14.08%
on 05/30/24
207.32 -15.49%
on 10/31/24
+20.27 (+13.08%)
since 12/22/23

Most Recent Stories

More News
Is AbbVie Stock a Buy?

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to offer to...

ABBV : 175.20 (-0.22%)
2 Excellent Dividend Stocks to Buy on the Dip

AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one...

ABBV : 175.20 (-0.22%)
AMGN : 261.38 (-0.76%)
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid...

ABBV : 175.20 (-0.22%)
PFE : 26.33 (-0.11%)
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called "Santa Claus rallies" can occur near the end...

NVO : 86.25 (+1.47%)
VRTX : 399.64 (+0.60%)
ABBV : 175.20 (-0.22%)
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...

MRK : 98.43 (+0.39%)
TEVA : 21.93 (-0.72%)
ABBV : 175.20 (-0.22%)
PFE : 26.33 (-0.11%)
SNY : 47.71 (-0.13%)
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline

The 2024 Canadian Headache Society (CHS) Migraine Prevention Guideline, which replaces the previous version published in 2012, granted strong recommendations...

ABBV : 175.20 (-0.22%)
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond

What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase....

ABT : 113.36 (-0.76%)
ABBV : 175.20 (-0.22%)
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...

JNJ : 143.78 (-0.48%)
TEVA : 21.93 (-0.72%)
ABBV : 175.20 (-0.22%)
SNY : 47.71 (-0.13%)
4 Big Drug Stocks That May Continue to Outperform in 2025

The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals...

LLY : 778.15 (+1.35%)
VRTX : 399.64 (+0.60%)
GILD : 92.51 (-0.06%)
ABBV : 175.20 (-0.22%)
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?

AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble Therapeutics, which will add the latter’s lead pipeline candidate, an oral...

NVO : 86.25 (+1.47%)
LLY : 778.15 (+1.35%)
ABBV : 175.20 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 184.17
2nd Resistance Point 180.49
1st Resistance Point 178.03
Last Price 175.20
1st Support Level 171.89
2nd Support Level 168.21
3rd Support Level 165.75

See More

52-Week High 207.32
Fibonacci 61.8% 186.79
Fibonacci 50% 180.45
Last Price 175.20
Fibonacci 38.2% 174.11
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar